OA09819A - Utilisation de la riboflavine dans le taitement de maladies liées aux virus hiv de l'herpès de la rétinite pigmentaire et du paludisme - Google Patents

Utilisation de la riboflavine dans le taitement de maladies liées aux virus hiv de l'herpès de la rétinite pigmentaire et du paludisme

Info

Publication number
OA09819A
OA09819A OA60422A OA60422A OA09819A OA 09819 A OA09819 A OA 09819A OA 60422 A OA60422 A OA 60422A OA 60422 A OA60422 A OA 60422A OA 09819 A OA09819 A OA 09819A
Authority
OA
OAPI
Prior art keywords
riboflavin
malaria
treatment
diseases related
retinitis pigmentosa
Prior art date
Application number
OA60422A
Other languages
English (en)
French (fr)
Inventor
Berque Jean
Original Assignee
Berque Jean
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berque Jean filed Critical Berque Jean
Publication of OA09819A publication Critical patent/OA09819A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
OA60422A 1991-04-02 1993-10-01 Utilisation de la riboflavine dans le taitement de maladies liées aux virus hiv de l'herpès de la rétinite pigmentaire et du paludisme OA09819A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9104218A FR2674753B1 (fr) 1991-04-02 1991-04-02 Nouvelles indications therapeutiques, en particulier pour le traitement du sida, d'un medicament deja existant et fabrique a partir d'une molecule denuee de contre-indications et d'effets indesirables.

Publications (1)

Publication Number Publication Date
OA09819A true OA09819A (fr) 1994-04-15

Family

ID=9411559

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60422A OA09819A (fr) 1991-04-02 1993-10-01 Utilisation de la riboflavine dans le taitement de maladies liées aux virus hiv de l'herpès de la rétinite pigmentaire et du paludisme

Country Status (7)

Country Link
EP (1) EP0578733A1 (ja)
JP (1) JPH06506212A (ja)
AU (1) AU1654092A (ja)
CA (1) CA2107078A1 (ja)
FR (1) FR2674753B1 (ja)
OA (1) OA09819A (ja)
WO (1) WO1992017173A2 (ja)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ244270A (en) * 1991-09-13 1995-07-26 Eisai Co Ltd Injectable composition comprising riboflavin
US5981601A (en) * 1992-05-28 1999-11-09 Centre For Molecular Biology And Medicine Method for enhancing cellular bioenergy
FR2696319B1 (fr) * 1992-10-02 1994-12-30 Jean Berque Utilisation de produits biologiques atoxiques et principalement de la riboflavine dans la fabrication des préservatifs et des gants de protection médico-chirurgicaux.
GB9321558D0 (en) * 1993-10-19 1993-12-08 Radopath Ltd Anti-viral agents
GB2319474A (en) * 1993-10-19 1998-05-27 Radopath Ltd Anti-viral agents
JPH07188052A (ja) * 1993-12-27 1995-07-25 Sanwa Kagaku Kenkyusho Co Ltd インターフェロン用作用効果増強剤及び該増強剤とインターフェロンとを含有する抗ウイルス活性増強組成物
US6258577B1 (en) 1998-07-21 2001-07-10 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers
US6277337B1 (en) 1998-07-21 2001-08-21 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
US6268120B1 (en) 1999-10-19 2001-07-31 Gambro, Inc. Isoalloxazine derivatives to neutralize biological contaminants
US7985588B2 (en) 2000-06-02 2011-07-26 Caridianbct Biotechnologies, Llc Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
TW590780B (en) 2000-06-02 2004-06-11 Gambro Inc Additive solutions containing riboflavin
US7648699B2 (en) 2000-06-02 2010-01-19 Caridianbct Biotechnologies, Llc Preventing transfusion related complications in a recipient of a blood transfusion
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
US6548241B1 (en) 2000-11-28 2003-04-15 Gambro, Inc. Storage solution containing photosensitizer for inactivation of biological contaminants
JP4278384B2 (ja) 2001-03-21 2009-06-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 ビタミンｂ２還元体を含む医薬

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2096712A1 (en) * 1970-06-29 1972-02-25 Giraux Georges Steroid/b group vitamin compsns - for prevention and treatment of skin-photosensitivity disorders
GB1431841A (en) * 1973-01-15 1976-04-14 Evans S C Ophthalmic-nutritional preparations
DE2559569A1 (de) * 1975-10-22 1977-04-28 Josef Hofmann Fluessiges futtermittel fuer brieftauben
US4500524A (en) * 1982-09-15 1985-02-19 Trustees Of Boston University Tranquilizing and reducing or preventing seizures
JPS59172417A (ja) * 1983-03-23 1984-09-29 Nisshin Kagaku Kk リボフラビン酪酸エステル含有軟カプセル
JPS61275228A (ja) * 1985-03-14 1986-12-05 バクスタ−、トラベノ−ル、ラボラトリ−ズ、インコ−ポレイテツド 治療用タンパク組成物中のビ−ルスの光動的不活性化
DE3542309A1 (de) * 1985-11-29 1987-06-04 Cardona Federico Dr Medizinisches antioxidativum
WO1991005536A2 (en) * 1989-10-06 1991-05-02 The Beth Israel Hospital Association Novel oxidized lipoproteins and methods for their preparation
AU6729290A (en) * 1989-11-09 1991-06-13 Schering-Plough Healthcare Products, Inc. Riboflavin as a tanning enhancer

Also Published As

Publication number Publication date
WO1992017173A3 (fr) 1993-01-07
JPH06506212A (ja) 1994-07-14
AU1654092A (en) 1992-11-02
FR2674753A1 (fr) 1992-10-09
EP0578733A1 (fr) 1994-01-19
WO1992017173A2 (fr) 1992-10-15
FR2674753B1 (fr) 1995-03-10
CA2107078A1 (fr) 1992-10-03

Similar Documents

Publication Publication Date Title
OA09819A (fr) Utilisation de la riboflavine dans le taitement de maladies liées aux virus hiv de l'herpès de la rétinite pigmentaire et du paludisme
FR2647808B1 (fr) Poxvirus recombinant et vaccin contre le virus de l'herpes contenant ce poxvirus
EP0831873A4 (en) COMBINATORY THERAPY FOR THE TREATMENT OF HIV AND OTHER VIRAL INFECTIONS
HU9503751D0 (en) Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection
HK1011025A1 (en) 5,11-Dihydro-6h-dipyrido¬3,2-b:2'3'-e¾¬1,4¾diazepines and their use in the preventionor treatment of hiv infection
BR9606769A (pt) Tablete e processos para tratamento de uma infecção de vírus do herpes em um humano e para preparação do tablete
FI923357A (fi) Framstaellning av fettsyramediciner
FR2643557B1 (fr) Utilisation de n-acylcysteines dans le traitement de maladies associees aux infections par hiv
ZA936592B (en) Nutrition for persons infected with human immunodeficiency virus
NZ310055A (en) Genetically altered feline immunodeficiency viruses and their use as an effective vaccine against feline immunodeficiency virus infection
EP0736600A3 (en) Use of an immunodeficiency suppressing virus which suppresses lymphokines (ISL) to prevent viral replicas, in particular those of retroviruses
PT983271E (pt) Hemissulfato carbociclico nucleosidico e a sua utilizacao no tratamento de infeccoes virais
DE69028993D1 (de) Verwendung von kaffein bei der behandlung von herpes-simplex-virusinfektionen
DE69004451D1 (de) Prophylaxe und Behandlung von Herpesvirus-Infektionen.
FR2684552B1 (fr) Utilisation de la d-fenfluramine et de derives de la fenfluramine dans le traitement de l'hypertension chez des sujets insulino-resistants.
EP0294538A3 (en) Use of nigericin in the treatment of viral diseases
ATE142503T1 (de) Arzneimittelzubereitung bei der behandlung von tonsillitis
IL97110A0 (en) Benzylphosphonic acid derivatives,compositions containing them and their use in treating viral diseases
FR2709964B1 (fr) Compositions pharmaceutiques antivirales proposées dans le traitement du SIDA et de l'Herpès.
AU2795892A (en) Cd36 immunoadhesins and their use in selectively killing (plasmodium falciparum) infected erythrocytes
AU6736096A (en) 1(hetero)aryl-4-(condensed thiazol-2-ylalkyl)-piperazine derivatives, their preparation and their use in the treatment of 5-ht1a-receptor mediated disorders
ZA9010337B (en) Fibroblast growth factor for use in the prevention and treatment of viral infections
AU641157B2 (en) 2-imino-thiadiazoline-5-sulphonamides and their use in the treatment of glaucoma
EP0425840A3 (en) Use of methenamine in the treatment of viral diseases and malign neoplasies
ZA935165B (en) Developments relating to human immunodeficiency viruses